6 research outputs found
Recommended from our members
Human Gain-of-Function MC4R Variants Show Signaling Bias and Protect against Obesity.
The melanocortin 4 receptor (MC4R) is a G protein-coupled receptor whose disruption causes obesity. We functionally characterized 61 MC4R variants identified in 0.5 million people from UK Biobank and examined their associations with body mass index (BMI) and obesity-related cardiometabolic diseases. We found that the maximal efficacy of β-arrestin recruitment to MC4R, rather than canonical Gαs-mediated cyclic adenosine-monophosphate production, explained 88% of the variance in the association of MC4R variants with BMI. While most MC4R variants caused loss of function, a subset caused gain of function; these variants were associated with significantly lower BMI and lower odds of obesity, type 2 diabetes, and coronary artery disease. Protective associations were driven by MC4R variants exhibiting signaling bias toward β-arrestin recruitment and increased mitogen-activated protein kinase pathway activation. Harnessing β-arrestin-biased MC4R signaling may represent an effective strategy for weight loss and the treatment of obesity-related cardiometabolic diseases
Obesity-associated GNAS mutations and the melanocortin pathway.
This is the final version. Available from Massachusetts Medical Society via the DOI in this record. BACKGROUND: GNAS encodes the Gαs (stimulatory G-protein alpha subunit) protein, which mediates G protein-coupled receptor (GPCR) signaling. GNAS mutations cause developmental delay, short stature, and skeletal abnormalities in a syndrome called Albright's hereditary osteodystrophy. Because of imprinting, mutations on the maternal allele also cause obesity and hormone resistance (pseudohypoparathyroidism). METHODS: We performed exome sequencing and targeted resequencing in 2548 children who presented with severe obesity, and we unexpectedly identified 22 GNAS mutation carriers. We investigated whether the effect of GNAS mutations on melanocortin 4 receptor (MC4R) signaling explains the obesity and whether the variable clinical spectrum in patients might be explained by the results of molecular assays. RESULTS: Almost all GNAS mutations impaired MC4R signaling. A total of 6 of 11 patients who were 12 to 18 years of age had reduced growth. In these patients, mutations disrupted growth hormone-releasing hormone receptor signaling, but growth was unaffected in carriers of mutations that did not affect this signaling pathway (mean standard-deviation score for height, -0.90 vs. 0.75, respectively; P = 0.02). Only 1 of 10 patients who reached final height before or during the study had short stature. GNAS mutations that impaired thyrotropin receptor signaling were associated with developmental delay and with higher thyrotropin levels (mean [±SD], 8.4±4.7 mIU per liter) than those in 340 severely obese children who did not have GNAS mutations (3.9±2.6 mIU per liter; P = 0.004). CONCLUSIONS: Because pathogenic mutations may manifest with obesity alone, screening of children with severe obesity for GNAS deficiency may allow early diagnosis, improving clinical outcomes, and melanocortin agonists may aid in weight loss. GNAS mutations that are identified by means of unbiased genetic testing differentially affect GPCR signaling pathways that contribute to clinical heterogeneity. Monogenic diseases are clinically more variable than their classic descriptions suggest. (Funded by Wellcome and others.).Wellcome TrustWellcome TrustResearch EnglandNational Institute for Health Researc
A rare human variant that disrupts GPR10 signalling causes weight gain in mice
This is the author accepted manuscript.Data availability:
Exome sequencing data are accessible from the European Genome Archive under a managed
access agreement (EGAS00001000124 and EGAS00001000825). Additional data that support
the findings of this study are available upon request from the corresponding authors (ISF and
SML).Disruption of brain-expressed G-protein-coupled receptor-10 (GPR10) causes obesity in
animals. Here, we identified multiple rare variants in GPR10 in people with severe obesity and
in normal weight controls. These variants impaired ligand binding and G-protein-dependent
signalling in cells. Transgenic mice harbouring a loss of function GPR10 variant found in an
obese individual, gained excessive weight due to decreased energy expenditure rather than
increased food intake. This evidence supports a role for GPR10 in human energy homeostasis.
Therapeutic targeting of GPR10 may represent an effective weight-loss strategy.Wellcome TrustNational Institute for Health Research (NIHR)Bernard Wolfe Health Neuroscience EndowmentBotnar FondationEvelyn TrustResearch EnglandFrench National Research AgencyNational Center for Precision Diabetic MedicineMedical Research Council (MRC)Biotechnology and Biological Sciences Research Council (BBSRC
Loss-of-function mutations in the melanocortin 4 receptor in a UK birth cohort.
Mutations in the melanocortin 4 receptor gene (MC4R) are associated with obesity but little is known about the prevalence and impact of such mutations throughout human growth and development. We examined the MC4R coding sequence in 5,724 participants from the Avon Longitudinal Study of Parents and Children, functionally characterized all nonsynonymous MC4R variants and examined their association with anthropometric phenotypes from childhood to early adulthood. The frequency of heterozygous loss-of-function (LoF) mutations in MC4R was ~1 in 337 (0.30%), considerably higher than previous estimates. At age 18 years, mean differences in body weight, body mass index and fat mass between carriers and noncarriers of LoF mutations were 17.76 kg (95% CI 9.41, 26.10), 4.84 kg m-2 (95% CI 2.19, 7.49) and 14.78 kg (95% CI 8.56, 20.99), respectively. MC4R LoF mutations may be more common than previously reported and carriers of such variants may enter adult life with a substantial burden of excess adiposity